Cover Image
市場調查報告書

全球肌肉萎縮性側索硬化症(俗稱漸凍人)(ALS)市場

Global Amyotrophic Lateral Sclerosis Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 294972
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
全球肌肉萎縮性側索硬化症(俗稱漸凍人)(ALS)市場 Global Amyotrophic Lateral Sclerosis Market 2014-2018
出版日期: 2014年01月17日 內容資訊: 英文 46 Pages
簡介

全球肌肉萎縮性側索硬化症(俗稱漸凍人)(ALS)市場,隨著全世界的人口的高齡化,預計從2013年到2018年,以5.39%的年複合成長率擴大。

本報告提供全球肌肉萎縮性側索硬化症(ALS)市場現狀與未來預測、成長要素與課題、主要供應商分析等等,為您概述為以下內容。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 地理區分

第8章 購買標準

第9章 罹患率和得病率

第10章 市場成長因素

第11章 成長因素與其影響

第12章 市場課題

第13章 成長因素與課題的影響

第14章 市場趨勢

第15章 趨勢與其影響

第16章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 其他卓越供應商
  • 供應商排行榜

第17章 Late Stage Pipeline Snapshot

第18章 主要供應商分析

  • Covis Pharmaceutical Inc.
  • Eisai
  • GlaxoSmithKline plc
  • 三菱田邊製藥

第19章 相關報告

目錄
Product Code: IRTNTR3207

TechNavio's analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Amyotrophic Lateral Sclerosis Drugs Market has also been witnessing the increasing awareness of ALS drugs. However, the patent expiry of Rilutek could pose a challenge to the growth of this market.

TechNavio's report, the Global Amyotrophic Lateral Sclerosis Drugs market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, EMEA and APAC regions; it also covers the Global Amyotrophic Lateral Sclerosis Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this space include Covis Pharmaceutical Inc., Eisai Co. Ltd., GlaxoSmithKline plc, and Mitsubishi Tanabe Pharma Corp.

Other vendors mentioned in the report are Amorfix Life Sciences Ltd., BrainStrom Cell Therapeutics Inc., Newron Pharmaceuticals S.p.A, Neuraltus Pharmaceuticals Inc., Nutra Pharma Corp., Oxford BioMedica plc, Pharnext SAS, and Q-Therapeutics Inc.

Key questions answered in this report:

  • What will the market size be in 2016/2018 and what will be the growth rate?
  • What are key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by key vendors?
  • What are the strengths and weaknesses of each of these key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Geographical Segmentation

08. Buying Criteria

09. Rate of Incidence and Prevalence

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape

  • 16.1. Competitive Scenario
    • 16.1.1. Key News
    • 16.1.2. Mergers and Acquisitions
  • 16.2. Other Prominent Vendors
  • 16.3. Vendor Ranking 2013

17. Late Stage Pipeline Snapshot

18. Key Vendor Analysis

  • 18.1. Covis Pharmaceutical Inc.
    • 18.1.1. Business Overview
    • 18.1.2. Key Information
    • 18.1.3. SWOT Analysis
  • 18.2. Eisai Co. Ltd.
    • 18.2.1. Business Overview
    • 18.2.2. Key Information
    • 18.2.3. SWOT Analysis
  • 18.3. GlaxoSmithKline plc
    • 18.3.1. Business Overview
    • 18.3.2. Business Segmentation
    • 18.3.3. Key Information
    • 18.3.4. SWOT Analysis
  • 18.4. Mitsubishi Tanabe Pharma Corp.
    • 18.4.1. Business Overview
    • 18.4.2. Business Segmentation
    • 18.4.3. Key Information
    • 18.4.4. SWOT Analysis

19. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global ALS Drugs Market 2013-2018 (US$ million)
  • Exhibit 3: Global ALS Drugs Market by Geographical Segmentation 2013
  • Exhibit 4: GlaxoSmithKline plc: Business Segmentation
  • Exhibit 5: Mitsubishi Tanabe Pharma Corp.: Business Segmentation
Back to Top